Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another Big Pharma Embraces AI As Exscientia Bags GSK

Executive Summary

GSK's deal with Exscientia will see the Scottish artificial intelligence pioneer discover new small molecules against targets selected by the big pharma. Exscientia is already working with Sanofi, Evotec, Sumitomo Dainippon Pharma and Sunovion across a range of disease areas, and is in talks with others.

You may also be interested in...



Evotec Invests €15m In AI-driven Exscientia

Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.

Deal Watch: Entasis, GARDP Partner On Novel Antibiotic For Drug-Resistant Gonorrhea

Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.

Quest To Use AI In Drug Discovery Joins Sanofi and Exscientia

Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel